Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vergil Brown

Internal Medicine Fort Walton Beach, FL Medical Doctor

NPI 1871578955 CMS profile 357892

1005 Mar Walt Dr, Internal Medicine, Fort Walton Beach, FL 32547

Open in the dashboard

General payments

$3,621

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vergil Brown of Fort Walton Beach, FL is reported in the CMS Open Payments database as having received $3,621 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $645 28
2024 General $851 43
2023 General $315 9
2022 General $606 38
2021 General $793 56
2020 General $352 19
2019 General $59 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vergil Brown
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Vergil Brown were reported at $645. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Vergil Brown Internal Medicine median Middle half National median
2019 $59 $159 $48–$570 $163
2020 $352 $119 $33–$402 $114
2021 $793 $135 $37–$521 $132
2022 $606 $141 $42–$496 $149
2023 $315 $149 $45–$519 $160
2024 $851 $154 $47–$537 $164
2025 $645 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $489 37 payments
  2. Dexcom, Inc. $480 16 payments
  3. Novo Nordisk Inc $400 22 payments
  4. AstraZeneca Pharmaceuticals LP $394 20 payments
  5. GlaxoSmithKline, LLC. $374 24 payments
  6. Pfizer Inc. $343 19 payments
  7. Lilly USA, LLC $277 17 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $182 10 payments
  9. Janssen Pharmaceuticals, Inc $149 10 payments
  10. CVRx, Inc. $125 1 payment
  11. Other $408 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,610 193 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Dexcom G6 Transmitter $404 11 payments
  2. EVENITY $289 23 payments
  3. TRELEGY ELLIPTA $266 15 payments
  4. Prolia $258 21 payments
  5. Ozempic $239 12 payments
  6. RYBELSUS $203 12 payments
  7. MOUNJARO $191 12 payments
  8. ELIQUIS $185 11 payments
  9. FARXIGA $168 12 payments
  10. Repatha $156 11 payments
  11. Other $2,580 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 142 drugs

Part D claims

8,781

Median for Internal Medicine: 777

Drug cost

$906,357

Median for Internal Medicine: $73,373

Branded share of claims

15.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 141 $179,203
Jardiance Empagliflozin Brand 92 $131,216
Humira Pen Adalimumab Brand 12 $88,038
Mounjaro Tirzepatide Brand 63 $78,748
Ozempic Semaglutide Brand 46 $64,481
Rybelsus Semaglutide Brand 16 $43,401
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $31,173
Prolia Denosumab Brand 18 $30,961
Xarelto Rivaroxaban Brand 32 $30,502
Myrbetriq Mirabegron Brand 22 $29,330

The 10 drugs with the highest cost, of 142 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$681,880

Of which drugs: $49,940

Medicare patients

957

Average age 78

Services billed

26,073

558 women, 399 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 46%
Diabetes 34%
Ischemic heart disease 32%
Atrial fibrillation 24%
COPD 21%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 37 2,280 $45,065
Vaccine for influenza for injection into muscle 90662 Office 57 58 $4,607

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $121
$121 — —
MOUNJARO
  • Lilly USA, LLC $78
$78 63 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $32
  • Lilly USA, LLC $30
$63 92 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $47
$47 29 —
EVENITY
  • Amgen Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record